ENTRY       D10928                      Drug
NAME        Erenumab (USAN/INN);
            Erenumab (genetical recombination) (JAN);
            Erenumab-aooe;
            Aimovig (TN)
PRODUCT     AIMOVIG (Amgen)
SEQUENCE    ï¿¼(Heavy chain)
            QVQLVESGGG VVQPGRSLRL SCAASGFTFS SFGMHWVRQA PGKGLEWVAV ISFDGSIKYS
            VDSVKGRFTI SRDNSKNTLF LQMNSLRAED TAVYYCARDR LNYYDSSGYY HYKYYGMAVW
            GQGTTVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS WNSGALTSGV
            HTFPAVLQSS GLYSLSSVVT VPSSNFGTQT YTCNVDHKPS NTKVDKTVER KCCVECPPCP
            APPVAGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVQFNWYVDG VEVHNAKTKP
            REEQFNSTFR VVSVLTVVHQ DWLNGKEYKC KVSNKGLPAP IEKTISKTKG QPREPQVYTL
            PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPMLDSD GSFFLYSKLT
            VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK
            (Light chain)
            QSVLTQPPSV SAAPGQKVTI SCSGSSSNIG NNYVSWYQQL PGTAPKLLIY DNNKRPSGIP
            DRFSGSKSGT STTLGITGLQ TGDEADYYCG TWDSRLSAVV FGGGTKLTVL GQPKANPTVT
            LFPPSSEELQ ANKATLVCLI SDFYPGAVTV AWKADGSPVK AGVETTKPSK QSNNKYAASS
            YLSLTPEQWK SHRSYSCQVT HEGSTVEKTV APTECS
            (Disulfide bridge: H22-H96, H144-L215, H157-H213, H232-H'232, H233-H'233, H236-H'236, H239-H'239, H270-H330, H376-H434, H'22-H'96, H'144-L'215, H'157-H'213, H'270-H'330, H'376-H'434, L22-L89, L138-L197, L'22-L'89, L'138-L'197)
  TYPE      Peptide
REMARK      Therapeutic category: 1190
            ATC code: N02CD01
            Product: D10928<JP/US>
EFFICACY    Antimigraine, Anti-calcitonin receptor-like receptor antibody
  TYPE      Monoclonal antibody
COMMENT     Prevention of migraine
TARGET      CALCRL [HSA:10203] [KO:K04577]
  PATHWAY   hsa04080(10203)  Neuroactive ligand-receptor interaction
            hsa04270(10203)  Vascular smooth muscle contraction
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N02 ANALGESICS
               N02C ANTIMIGRAINE PREPARATIONS
                N02CD Calcitonin gene-related peptide (CGRP) antagonists
                 N02CD01 Erenumab
                  D10928  Erenumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antimigraine Agents
              Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
               Erenumab
                D10928  Erenumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              11  Agents affecting central nervous system
               119  Miscellaneous
                1190  Miscellaneous
                 D10928  Erenumab (USAN/INN); Erenumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Secretin receptor family
               Calcitonin
                CALCRL
                 D10928  Erenumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10928
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10928
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10928
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10928
DBLINKS     CAS: 1582205-90-0
            PubChem: 342581785
///
